Sugi Predict

Sugi Predict / Compounds / SCHEMBL2210144

SCHEMBL2210144

SCHEMBL2210144

COc1cc(OC)c2c(Cl)ccnc2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SRC P12931 3/20 0.51
▸ PDGFRB P09619 3/20 0.42
▸ PDGFRA P16234 3/20 0.42
▸ MAPT P10636 2/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ CYP1A2 P05177 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ HPGD P15428 1/20 0.42
▸ ALOX15 P16050 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ CASP1 P29466 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ HSD17B10 Q99714 1/20 0.42
▸ PDE3B Q13370 1/20 0.41
▸ PDE3A Q14432 1/20 0.41
▸ CCR1 P32246 1/20 0.39
▸ CCR5 P51681 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30509466 1.00 SRC (0.51) SRCPDGFRBPDGFRAMAPTKDM4E
SCHEMBL4758602 0.83 SRC (0.43) SRCPDGFRBPDGFRAMAPTMEN1
SCHEMBL9299522 0.81 PDE3B (0.45) SRCPDGFRBPDGFRAMAPTKDM4E
SCHEMBL2204818 0.80 ESR2 (0.45) SRCPDGFRBPDGFRAMAPTKDM4E
SCHEMBL11729820 0.76 TGFBR1 (0.48) SRCKDM4EALDH1A1HPGDDOT1L
SCHEMBL18639840 0.75 RIPK2 (0.38) SRCMAPTRIPK2
SCHEMBL30353909 0.75 SRC (0.56) SRCMAPTKDM4EMEN1ALDH1A1
SCHEMBL7699141 0.75 PDE3B (0.49) SRCMAPTKDM4EMEN1ALDH1A1
SCHEMBL1803647 0.75 SRC (0.56) SRCMAPTKDM4EMEN1ALDH1A1
SCHEMBL9073416 0.73 HSP90AA1 (0.50) SRCPDGFRBPDGFRAMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025123007-A1 RAS INHIBITORS AND METHODS OF USE THEREOF KESTREL THERAPEUTICS INC. (US) 2025-06-12 — — WO disclosed
US-20230339900-A1 CASEIN KINASE 1 DELTA MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2023-10-26 — — US disclosed
EP-4214199-A1 CASEIN KINASE 1 DELTA MODULATORS JANSSEN Pharmaceutica NV (BE) 2023-07-26 — — EP disclosed
CN-116490503-A Casein kinase 1 delta modulators 詹森药业有限公司 2023-07-25 — — CN disclosed
US-10017496-B2 Uracil derivatives as AXL and c-MET kinase inhibitors IGNYTA, INC. (US) 2018-07-10 — — US disclosed
US-10017496-B2 Uracil derivatives as AXL and c-MET kinase inhibitors IGNYTA, INC. (US) 2018-07-10 — — US disclosed
US-10017496-B2 Uracil derivatives as AXL and c-MET kinase inhibitors IGNYTA, INC. (US) 2018-07-10 — — US disclosed
US-20170320853-A1 URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS IGNYTA, INC. (US) 2017-11-09 — — US disclosed
US-20170320853-A1 URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS IGNYTA, INC. (US) 2017-11-09 — — US disclosed
US-20170320853-A1 URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS IGNYTA, INC. (US) 2017-11-09 — — US disclosed
EP-2137177-A2 AURORA KINASE MODULATORS AND METHOD OF USE Amgen, Inc (US) 2009-12-30 — — EP disclosed
US-20090076075-A1 QUINOLINE DERIVATIVES ASTRAZENECA AB (SE) 2009-03-19 — — US disclosed
US-20090069297-A1 Aurora kinase modulators and method of use AMGEN INC. (US) 2009-03-12 — — US disclosed
US-20090069297-A1 Aurora kinase modulators and method of use AMGEN INC. (US) 2009-03-12 — — US disclosed
US-20090069297-A1 Aurora kinase modulators and method of use AMGEN INC. (US) 2009-03-12 — — US disclosed
EP-1994024-A2 QUINOLINE DERIVATIVES AstraZeneca AB (SE) 2008-11-26 — — EP disclosed
WO-2008124083-A2 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC. (US) 2008-10-16 — — WO disclosed
WO-2008124083-A2 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC. (US) 2008-10-16 — — WO disclosed
WO-2007099323-A2 QUINOLINE DERIVATIVES ASTRAZENECA AB (SE) 2007-09-07 — — WO disclosed
EP-0860433-B1 QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF GROWTH FACTOR RECEPTOR ORIGINATING IN PLATELET AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME KIRIN BREWERY (JP) 2002-07-03 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069297-A1 Aurora kinase modulators and method of use AURKC, AURKA, CDK1 SRC 447/4885PDGFRB 1235/4885PDGFRA 1102/4885
US-20090076075-A1 QUINOLINE DERIVATIVES RECQL, NQO2, NRAS SRC 1968/4885PDGFRB 1820/4885PDGFRA 1096/4885
US-20230339900-A1 CASEIN KINASE 1 DELTA MODULATORS CSNK1D, CSNK1A1, CSNK2A1 SRC 392/4885PDGFRB 1145/4885PDGFRA 718/4885
US-20170320853-A1 URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS AXL, RET, FLT3 SRC 15/4885PDGFRB 28/4885PDGFRA 72/4885
US-10017496-B2 Uracil derivatives as AXL and c-MET kinase inhibitors AXL, RET, FLT3 SRC 15/4885PDGFRB 28/4885PDGFRA 72/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.